Results

Total Results: 2,080 records

Showing results for "drug".

41. Appendix-F1-Surveillance-Report-1 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/appendix-f1-surveillance-report-1.xlsx
    November 22, 2021 - Class 1 Drug Class 2 Drug 1 Drug 2 Measure Name Measure Scale Assessment Time (wk) Time Category Grp … Class 1 Drug Class 2 Drug 1 Drug 2 Measure Name Measure Scale Assessment Time (wk) Time Category Grp … Class 1 Drug Class 2 Drug 1 Drug 2 Measure Name Measure Scale Assessment Time (wk) Time Category Grp … Class 1 Drug Class 2 Drug 1 Drug 2 Measure Name Measure Scale Assessment Time (wk) Time Category Grp … Class 1 Drug Class 2 Drug 1 Drug 2 Measure Name Measure Scale Assessment Time (wk) Time Category Grp

42. App-F1-Surv-Report-1-Nonopioid-Pharmacol-Chronic-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f1-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
    September 20, 2022 - Pain severity for neuropathic pain Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug … Sleep outcomes for neuropathic pain Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug … Pain severity for fibroyalgia Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug 1 … Anxiety outcomes for fibromyalgia Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug … Sleep outcomes for fibromyalgia Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug

43. App-F1-Surv-Report-2-Nonopioid-Pharmacol-Chronic-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f1-surv-report-2-nonopioid-pharmacol-chronic-pain.xlsx
    September 20, 2022 - Pain severity for neuropathic pain Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug … Sleep outcomes for neuropathic pain Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug … Pain severity for fibromyalgia Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug 1 … Anxiety outcomes for fibromyalgia Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug … Sleep outcomes for fibromyalgia Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug

44. App-F1-Surv-Report-3-Nonopioid-Pharmacol-Chronic-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f1-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
    September 20, 2022 - Pain severity for neuropathic pain Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug … Sleep outcomes for neuropathic pain Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug … Pain severity for fibromyalgia Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug 1 … Anxiety outcomes for fibromyalgia Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug … Sleep outcomes for fibromyalgia Author, Year Quality Pain Population Drug Class 1 Drug Class 2 Drug

45. Effective Health Care Program
    effectivehealthcare.ahrq.gov/health-topics/psoriasis-0
    November 19, 2007 - Comparative Effectiveness of Drug Therapy for Rheumatoid Arthritis and Psoriatic Arthritis in Adults

46. Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/alcohol-misuse-drug-therapy/research/

47. Appendix-F2-Surveillance-Report-1 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/appendix-f2-surveillance-report-1.xlsx
    November 22, 2021 - Constipation Constipation Weight Gain Weight Gain Weight Gain Author, Year Quality Pain Population Drug … Class Drug Assessment Time (wk) Time Category n N n N Specific AE n N N Randomized Specific AE n N N … Class Drug Assessment Time (wk) Time Category n N n N Specific AE n N N Randomized Specific AE n N N … Class Drug Assessment Time (wk) Time Category n N n N Specific AE n N N Randomized Specific AE n N N … Class Drug Assessment Time (wk) Time Category n N n N n N N Randomized Specific AE n N N Randomized

48. App-F2-Surv-Report-1-Nonopioid-Pharmacol-Chronic-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f2-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
    September 20, 2022 - Harms of tricyclic antidepressants versus placebo Author, Year Quality Pain Population Drug Class Drug … Harms of pregabalin versus placebo Author, Year Quality Pain Population Drug Class Drug Assessment Time … Harms of pregabalin versus amitriptyline Author, Year Quality Pain Population Drug Class Drug Assessment … Harms of pregabalin CR versus IR Author, Year Quality Pain Population Drug Class Drug Assessment Time … Harms of cannabis versus placebo Author, Year Quality Pain Population Drug Assessment Time (Wk) Time

49. Chicago-Area DEcIDE Center (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/off-label-use-research-priorities_research.pdf
    May 01, 2009 - and drug interactions. … Food and Drug Administration, Center for Drug Evaluation and Review. … /Drug Safety Diane Kennedy, RPh, MPH Food and Drug Administration Regulator/Drug Analysis Laurie … has serious side effects.** 2) The drug has frequent side effects. 3) The drug has serious drug-drug … interactions.** 4) The drug has frequent drug-drug interactions.* 5) The drug is approved in other

50. Data Points #8: Utilization of antihypertensive drug classes among Medicare beneficiaries with hypertension, 2007 to 2009 | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/hypertension-drugs-utilization/research
    November 16, 2011 - Data Points #8: Utilization of antihypertensive drug classes among Medicare beneficiaries with hypertension … of Medicare beneficiaries with hypertension used at least one prescription for an antihypertensive drug … Beneficiaries with hypertension used on average 1.9 ± 1.3 antihypertensive drug classes within a calendar … The top three dispensed antihypertensive drug classes were beta blockers, diuretics, and angiotensin-converting … In 2009, the total drug cost for antihypertensive agents was $4.3 billion and the out-of-pocket expenditure

51. App-F2-Surv-Report-3-Nonopioid-Pharmacol-Chronic-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-f2-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
    September 20, 2022 - Harms of tricyclic antidepressants versus placebo Author, Year Quality Pain Population Drug Class Drug … Harms of pregabalin versus placebo Author, Year Quality Pain Population Drug Class Drug Assessment Time … Harms of pregabalin versus amitriptyline Author, Year Quality Pain Population Drug Class Drug Assessment … Harms of pregabalin CR versus IR Author, Year Quality Pain Population Drug Class Drug Assessment Time … Harms of naproxen versus placebo Author, Year Quality Pain Population Drug Class Drug Assessment Time

52. S96 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/s96.pdf
    October 01, 2007 - Key Words: adverse drug reaction reporting systems, surveillance, drug safety (Med Care 2007;45: S96 … –S102) An adverse drug event (ADE) occurs when a drug intendedfor therapeutic use has an unintended … or a drug-specific effect. … How the US Food and Drug Administration defines and detects adverse drug events. … Incidence of adverse drug events and potential adverse drug events. Implications for prevention.

53. S9 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/s9.pdf
    October 01, 2007 - drug subsidy. … Coverage for the prescription drug benefit is provided under various types of prescription drug plans … ) prescription drug plans (MA-PDPs), which offer prescription drug coverage that is integrated with the … Medicare Part D Prescription Drug Event (PDE) Data. … Total Medicare Beneficiaries With Drug Coverage as of June 11, 2006 Description June (Millions) Drug

54. S13 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/s13.pdf
    October 01, 2007 - , or the drug indication itself. … to prove drug efficacy (ie, the possibility of a beneficial effect in an ideal setting), but not drug … effec- tiveness (ie, whether the drug works in reality).3 Further, information on comparative drug effectiveness … type, how long the drug has been taken, how recently the drug was taken, and demographics of the patient … US Food and Drug Administration.

55. Data-Points-9 Maps (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/data-points-9_maps.pdf
    March 29, 2012 - 2009 Annual Utilization of Sulfonylureas Among Diabetic Beneficiaries With At Least One Antidiabetic Drug … Annual Utilization of Sulfonylureas Among Diabetic Beneficiaries With At Least One Antidiabetic Drug … Annual Utilization of Sulfonylureas Among Diabetic Beneficiaries With At Least One Antidiabetic Drug … Annual Utilization of Sulfonylureas Among Diabetic Beneficiaries With At Least One Antidiabetic Drug … Annual Utilization of Insulin Among Diabetic Beneficiaries With At Least One Antidiabetic Drug

56. Cover Page (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/it-architecture-for-post-marketing-surveillance-arizona-cert.pdf
    September 01, 2007 - for monitoring and detecting adverse drug events. … Detecting adverse drug events is a difficult problem. … interactions and monitoring drug safety. … (Center for Drug Evaluation and Research [CDER], 2005). … Reporting mechanisms need to be customized for each drug and drug combinations to collect relevant

57. Cover Page (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/medicine-safety-call-center_research.pdf
    September 01, 2007 - for monitoring and detecting adverse drug events. … Detecting adverse drug events is a difficult problem. … interactions and monitoring drug safety. … (Center for Drug Evaluation and Research [CDER], 2005). … Reporting mechanisms need to be customized for each drug and drug combinations to collect relevant

58. Integrating stakeholder preferences in comparative effectiveness research using multi-criteria decision analysis (MCDA) and Conjoint Analysis (CA) (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/mcda-ijzerman.pdf
    January 01, 2011 - pressure 3 US$ Drug C partial relief No adverse events 5 US$ Slide … use) of a drug to its impact of treatment (e.g., drug requires complex dosing schedule and monitoring … use) of a drug to its impact of treatment (e.g., drug requires complex dosing schedule and monitoring … This screen is titled: Goal: Select the best drug treatment. … Clinical Benefit (symptom relieve due drug use) Impact of Treatment (e.g. drug requires complex dosing

59. Treatment for Bipolar Disorder in Adults: A Systematic Review | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/bipolar-disorder-treatment/final-report-2018
    August 07, 2018 - Purpose of Review To assess the effectiveness of drug and nondrug therapies for treating acute mania … Depression treatment: Evidence was insufficient for drug treatments for depressive episodes in adults … Assess the effect of drug and nondrug interventions for treating acute symptoms associated with bipolar … All other drug comparisons to placebo or active controls for acute mania, depression, and maintenance … All antipsychotics approved by the Food and Drug Administration, except aripiprazole, had low-strength

60. Medication Therapy Management | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/medication-therapy-management/research-protocol
    July 24, 2013 - 545.1 KB Background and Objectives for the Systematic Review The Medicare Prescription Drug … Public Law 108-173) 1 established the requirements that Part D plan sponsors must meet with regard to drug … substitution issue; complex regimen that can be simplified with same therapeutic benefit; and potential for drug-drug … : needed drug initiated; unnecessary drug discontinued; change in drug dose, form, or frequency; or generic … Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Public Law 108-173.